Lior Carmon, Vaxil Biotherapeutics Ltd., Nes-Ziona, Israel
Phase I/II study of Immucin, a pan-HLA, anti-MUC1 signal peptide vaccine in MM patients with residual disease or progression following autologous stem cell transplant.
Date: 2014-01-30 22:28:26 |